- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07672457
Substance Use Prevention for Recently Displaced Adults - SUPRA (R33) RCT (SUPRA RCT R33)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The war in Ukraine has provoked the world's current largest humanitarian displacement: since February 2022, over 13 million people, i.e., one-third of Ukrainians, have been forced to leave their homes, resulting in nearly 6 million internally displaced persons (IDPs). War and humanitarian emergencies may exacerbate substance use, but the incidence and prevalence of unhealthy substance use in humanitarian settings, including Ukraine, are currently largely unknown. This lack of data limits the ability to tailor targeted, effective preventive substance use interventions for these mobile populations. Addressing this knowledge gap is an immense priority for Ukraine, where rates of substance use were high even prior to the Russian invasion in February 2022, and in other settings hosting large populations of IDPs, including the United States.
To determine the feasibility, acceptability, and preliminary effectiveness of the intervention among IDPs, a RCT to evaluate implementation and substance use outcomes associated with the intervention at 1 and 6 months.
The investigators hypothesize that an ACT-based intervention delivered in a humanitarian context will help displaced persons in Ukraine build skills to manage stress and prevent or reduce substance use behaviors, ultimately mitigating the onset of substance use disorders.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Karsten Lunze, MD DrPH MPH
- Número de teléfono: 617-414-6933
- Correo electrónico: lunze@bu.edu
Copia de seguridad de contactos de estudio
- Nombre: Kimberly Hook, PhD MA
- Correo electrónico: kmhook@hsph.harvard.edu
Ubicaciones de estudio
-
-
-
Kyiv, Ucrania
- Alliance for Public Health
-
Contacto:
- Pavlo Smyrnov
- Número de teléfono: +380 44 490-5485
- Correo electrónico: Smyrnov@aph.org.ua
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age 18 or over
- Have been displaced at least once due to Anti-Terrorist Operation (ATO) or full-scale invasion since 2014
- Self-reported use of at least one substance other than alcohol and tobacco within the past 3 months
- Ability to provide informed consent and speak Ukrainian or Russian
Exclusion Criteria:
- Self-reported diagnosis of a substance use disorder
- Inability to provide informed consent
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: ACT Therapy
Participants randomized to this group will receive the ACT intervention
|
The ACT group intervention will involve a mixture of didactic instruction, discussion, and experiential activities.
ACT will help internally displaced persons to manage stress and prevent or reduce substance use behaviors, ultimately mitigating the onset of substance use disorders.
|
|
Comparador activo: Attention Control
Participants in the control group will receive minimally enhanced usual care to receive treatment as usual enhanced by a health information group session.
|
Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility of the ACT Intervention
Periodo de tiempo: 1 month and 6 months
|
Feasibility will be assessed using the 14-item feasibility subscales of the Applied Mental Health Research Group Implementation Measure (AMHR-IM).
Each item is rated on a 4-point scale where "0" means "not at all" and "3" means "a lot".
The overall Feasibility score is calculated as the mean (average) across all 14 completed items, where higher scores (closer to 3) reflect a higher level of perceived feasibility of the intervention.
|
1 month and 6 months
|
|
Acceptability of the ACT Intervention
Periodo de tiempo: 1 month and 6 months
|
Acceptability will be assessed using the 17-item acceptability subscales of the Applied Mental Health Research Group Implementation Measure (AMHR-IM).
Each item is rated on a 4-point Likert scale where "0" means "not at all" and "3" means "a lot".
The overall Acceptability score is calculated as the mean (average) across all 17 completed items, where higher scores (closer to 3) reflect a higher level of perceived acceptability of the intervention.
|
1 month and 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Karsten Lunze, MD DrPH MPH, Boston University Chobanian & Avedisian School of Medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- H-46965
- R33DA059856 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .